Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation (NCT04583046) | Clinical Trial Compass
CompletedNot Applicable
Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation
South Korea78 participantsStarted 2020-11-02
Plain-language summary
One lung ventilation (OLV) is essential during thoracic surgery. During OLV, intrapulmonary shunt can be increased resulting hypoxemia. Although OLV technique had been advanced so far, hypoxemia during OLV reaches about 10% in spite of inspired oxygen fraction 100%. Iloprost is a prostaglandin analogue used for pulmonary hypertension, which can decrease pulmonary artery resistance by selectively dilating pulmonary artery. In this prospective, randomized, double blind study, the investigator is planning to investigate the effects of iloprost on respiratory physiology (intrapulmonary shunt, deadspace, oxygenation, etc) in obese patients.
Who can participate
Age range40 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. scheduled for VATS lobectomy
✓. 40 \< age \< 80
✓. American Society of Anaesthesiologists(ASA) physical status classification I\~III
✓. BMI \> 30 kg /m2
Exclusion criteria
✕. American Society of Anaesthesiologists(ASA) physical status classification IV or more
✕. NYHA class III\~IV
✕. Severe obstructive lung disease and/or restrictive lung disease patients